Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Phase II "Proof of Concept", National Multi-centered. Randomised 1:1, Evaluate Whether Dapagliflozin Reduces Chemotherapy Induced Cardiotoxicity in Participants With Breast Cancer Treated With (Neo-) Adjuvant Anthracycline-based Chemotherapy +/- Trastuzumab

NCT06341842 is registered in ClinicalTrials.gov with Fondazione IRCCS Policlinico San Matteo di Pavia as lead sponsor.

NCT NCT06341842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06341842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Phase II "Proof of Concept", National Multi-centered. Randomised 1:1, Evaluate Whether Dapagliflozin Reduces Chemotherapy Induced Cardiotoxicity in Participants With Breast Cancer Treated With (Neo-) Adjuvant Anthracycline-based Chemotherapy +/- Trastuzumab
Lead sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase
Phase 2
Overall status
Unknown status
Start date
October 19, 2023
Completion date
April 19, 2025
Enrollment
316 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer